Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Tartarone, Alfredo, Lapadula, Vittoria, Di Micco, Concetta, Rossi, Gemma, Ottanelli, Carlotta, Marini, Andrea, Giorgione, Roberta, Ferrari, Katia, Catalano, Martina, Voltolini, Luca, Mini, Enrico, Roviello, Giandomenico
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176852/
https://ncbi.nlm.nih.gov/pubmed/34094913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.632256
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars